Canine atopic dermatitis is a common diagnosis, affecting as much as 3-10% of the canine population. Allergen-specific immunotherapy (ASIT) via subcutaneous injection – “allergy shots” – has efficacy in as many as 70% of treated patients; however, it requires weekly to twice-monthly injections. Owners who find injections difficult to administer, or who are frightened of needles, can turn to sublingual immunotherapy (SLIT).
Sublingual immunotherapy for pets is presented as a guide for veterinarians. The text describes canine atopic dermatitis as a common diagnosis and notes that allergen-specific immunotherapy by subcutaneous injection has efficacy in as many as 70% of treated patients but requires frequent injections. It introduces sublingual immunotherapy, or “allergy drops,” as a form of allergen-specific immunotherapy and compares its glycerin-stabilized formulation with the phenol-saline extracts used for injection.
The document reviews the sublingual route in humans, including antigen uptake by dendritic cells, regulatory T-cells, and cytokines such as IL-10. It also reviews efficacy evidence, citing double-blind, placebo-controlled SLIT studies and a Cochrane review that found SLIT reduced symptoms by 42 percent and medication need by 43 percent.
It is a form of allergen-specific immunotherapy, often called “allergy drops,” in which specific antigens placed under the tongue induce immunologic tolerance.
Across all trials, SLIT reduced symptoms by 42 percent and reduced medication need by 43 percent.
ASIT has been used in dogs, cats and horses for over 40 years.
No. Allergy shots use phenol-saline based allergen extracts, while SLIT is formulated with glycerin-stabilized extracts in a vehicle that augments uptake through the oral mucosa.